Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Replacing bleomycin with brentuximab vedotin (Adcetris) in the standard treatment regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) significantly improved overall survival (OS) in ...

Disitamab vedotin achieved ORR 54.9% (HER2-positive) and 52.6% (HER2-low), with complete responses 16.9% and 18.4%, supporting efficacy beyond strictly HER2-amplified tumors. Clinical benefit was ...

Seagen Inc. SGEN along with Japanese partner Astellas Pharma, Inc announced that the European Medicines Agency (“EMA”) has accepted the marketing authorization application (“MAA”) for their ...

With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine. While cisplatin ...

Read more on antibody drug conjugates in urothelial carcinoma where enfortumab vedotin and disitamab vedotin show high ...

Zilovertamab vedotin plus R-GemOx showed a 56.3% objective response rate in relapsed/refractory DLBCL patients, with a 50% complete response rate at the recommended phase 2 dose. The median duration ...

Please provide your email address to receive an email when new articles are posted on . More than one-third of patients achieved pathologic complete response and half achieved pathologic downstaging.

The FDA has approved enfortumab vedotin (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) or subcutaneous pembrolizumab (Keytruda Qlex, Merck) for the neoadjuvant and ...

The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie) for locally advanced or metastatic nonsquamous non–small cell lung cancer ...